RRCancer-Banque Cancers Gynécologiques-LDI/JGH, Canada

Certification Status: Approved
Registration Status: Completed

Objective: The rapid increase in global cancer represents a significant challenge for health systems worldwide. Cancer has now become the first cause of mortality in western countries, accounting for one third of all causes of death. Ovarian cancer (OC) is the deadliest of all gynecological cancers and 5th leading cause of cancer mortality in women. This cancer appears after a long latency with a mean age of incidence of ~58 years (1, 2) and early detection of the disease is non-existent. In studies with tissues or cells isolated from advanced stage OC, it has been difficult to segregate the changes related to disease initiation from other factors like progression and metastasis. The molecular pathways for early initiation or late progression of ovarian tumors are also unknown. The research community working on ovarian cancer in Canada is interested in a large scale, cooperative Canada-wide biomarker program

Registered Biobank Name RRCancer-Banque Cancers Gynécologiques-LDI/JGH
Biobank Leader Amber Yasmeen
Country Canada
Email for biobank inquiries walter.gotlieb@mcgill.ca
Principal Investigator Walter H.Gotlieb
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.
Biospecimen Collected: